Blocking SIRT1 to slow childhood medulloblastoma
Targeting histone deacetylase SIRT1 in medulloblastoma
['FUNDING_R01'] · GEORGE WASHINGTON UNIVERSITY · NIH-11247564
This project looks at whether turning down a protein called SIRT1 can stop or slow the growth of a common childhood brain tumor called medulloblastoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11247564 on ClinicalTrials.gov |
What this research studies
Researchers at George Washington University are studying a protein named SIRT1 that helps control cell growth and may drive some medulloblastomas. In the lab they will map how SIRT1 alters cell structures called centrosomes and cilia by changing other proteins (including PLK2 and CCDC66). The team will test how changing SIRT1 activity affects tumor cells in dishes and in animal models, with a focus on the sonic hedgehog (SHH) subtype of medulloblastoma. The goal is to see whether targeting SIRT1 could lead to new treatment strategies for this subtype.
Who could benefit from this research
Good fit: Children with medulloblastoma—especially those whose tumors are classified as the SHH subtype—are the most directly relevant group for this research.
Not a fit: Patients with non-SHH medulloblastoma subtypes or unrelated brain conditions are less likely to benefit from findings specific to SIRT1 and SHH-driven tumors.
Why it matters
Potential benefit: If successful, this work could point to new ways to slow or stop growth of SHH-subtype medulloblastoma and lead to future therapies for children with this tumor.
How similar studies have performed: Laboratory studies in several cancers have linked SIRT1 to tumor growth and some early preclinical work supports targeting SIRT1, but applying this approach to medulloblastoma is relatively new and not yet tested in people.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SETO, EDWARD — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: SETO, EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.